0
Letters |

Prevention of Cervical Cancer in Low-Resource SettingsPrevention of Cervical Cancer in Low-Resource Settings

JAMA. 2006;295(11):1248-1249. doi:10.1001/jama.295.11.1248-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

PREVENTION OF CERVICAL CANCER IN LOW-RESOURCE SETTINGS

To the Editor: Dr Denny and colleagues1 reported the safety and efficacy of a resource-appropriate approach for cervical cancer screening designed for less-developed countries. This is important because although cervical cancer incidence has decreased significantly in recent decades in economically developed countries, it has remained a major social and economic burden in low-resource countries.2

The introduction of appropriate screening methods and strategies available for low-income women and low-resource countries has become an important challenge in terms of safety, efficacy, and cost-effectiveness in Hungary, which is considered to have a transitional or developing economy. The National Health Insurance Fund Administration, the health care financing agency in Hungary, conducted a cost-effectiveness analysis of cervical cancer screening (including cytologic testing and colposcopy).3 Although the cost per life-year saved was considered to be acceptable, it remained necessary to analyze the budget impact of such a screening program.

We compared the 2001 national treatment cost of cervical and breast cancer in Hungary with an estimate of national direct costs of potential organized screening programs.4 We found that these programs would add a substantial amount to the current expenditures for these conditions. For breast cancer, the annual treatment cost (US $29.9 million) was far higher than the estimated cost of a screening program (US $5.8 million). However, for cervical cancer, the direct cost alone of a screening program with only a 75% participation rate (US $4.5 million) might be higher than the 2001 cost of treatment (US $3.6 million).

Although Hungary decided to implement an organized national cervical cancer screening program, in a country with a transitional economy or low resources the short-term budgetary constrain approach (“budget silo”)5 may be more important for decision makers than a long-term cost-effectiveness approach.

Financial Disclosures: None reported.

References
Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial.  JAMA. 2005;2942173-2181
PubMed
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.  CA Cancer J Clin. 2005;5574-108
PubMed
Boncz I, Sebestyén A, Pál M, Sándor J, Ember I. Health-economic analysis of cervical cancer screening [in Hungarian].  Orv Hetil. 2003;144713-717
PubMed
Boncz I, Sebestyén A, Ember I. Cost analysis of treatment and screening of breast and cervical cancer in Hungary.  Anticancer Res. 2004;243439-3440
Garrison L, Towse A. The drug budget silo mentality in Europe: an overview.  Value Health. 2003;6(suppl 1)  S1-S9
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial.  JAMA. 2005;2942173-2181
PubMed
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.  CA Cancer J Clin. 2005;5574-108
PubMed
Boncz I, Sebestyén A, Pál M, Sándor J, Ember I. Health-economic analysis of cervical cancer screening [in Hungarian].  Orv Hetil. 2003;144713-717
PubMed
Boncz I, Sebestyén A, Ember I. Cost analysis of treatment and screening of breast and cervical cancer in Hungary.  Anticancer Res. 2004;243439-3440
Garrison L, Towse A. The drug budget silo mentality in Europe: an overview.  Value Health. 2003;6(suppl 1)  S1-S9
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.